BioCatalystFeed / Readout calendar / FDA decisions / Drugs / Disease areas / Companies / Months
Biliary tract cancer clinical trials and catalysts
Active industry-sponsored trials on ClinicalTrials.gov for biliary tract cancer: 95 (67 sponsors; 13 newly posted in the last 180 days, 1 stopped in the last 180 days; 9 new-entrant sponsors). Momentum score 13.2, rank 53 of 91 on the disease-area ranking. As of 2026-11-18.
Phase distribution: Early Phase 1 0, Phase 1 20, Phase 2 53, Phase 3 15, Phase 4 2, N/A 5.
Most active sponsors, by phase
| Sponsor | Active trials | By phase | New (window) | Upcoming readouts |
|---|---|---|---|---|
| AstraZeneca AZN | 14 | P2 7, P3 5, NA 2 | 0 | 2 |
| Sichuan Baili Pharmaceutical Co., Ltd. | 3 | P2 1, P3 2 | 1 | 1 |
| Suzhou Suncadia Biopharmaceuticals Co., Ltd. | 4 | P2 3, P3 1 | 0 | 1 |
| Akeso | 2 | P2 1, P3 1 | 0 | 1 |
| Taiho Pharmaceutical Co., Ltd. | 2 | P3 1, P1 1 | 1 | 0 |
| Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | 1 | P3 1 | 0 | 1 |
| Compass Therapeutics COMP | 1 | P3 1 | 0 | 0 |
| InnoPharmax Inc. | 1 | P3 1 | 0 | 0 |
| J-Pharma Co., Ltd. | 1 | P3 1 | 0 | 0 |
| Jazz Pharmaceuticals JAZZ | 1 | P3 1 | 0 | 0 |
| Merck Sharp & Dohme LLC MRK | 3 | P4 1, P2 2 | 1 | 1 |
| AbbVie ABBV | 2 | P1 2 | 1 | 0 |
| Amgen AMGN | 2 | P2 1, P1 1 | 0 | 1 |
| Eli Lilly and Company LLY | 2 | P2 2 | 0 | 1 |
| Seagen, a wholly owned subsidiary of Pfizer | 2 | P2 2 | 0 | 0 |
| SystImmune Inc. | 2 | P1 2 | 0 | 1 |
| Yuhan Corporation | 2 | P2 2 | 0 | 0 |
| 3D Medicines (Sichuan) Co., Ltd. | 1 | P2 1 | 0 | 0 |
| AccSalus Biosciences, Inc. | 1 | P1 1 | 0 | 0 |
| Actithera INC. new entrant | 1 | P2 1 | 1 | 0 |
| Astellas Pharma Global Development, Inc. | 1 | P2 1 | 0 | 1 |
| Avenzo Therapeutics, Inc. | 1 | P2 1 | 0 | 0 |
| Bayer | 1 | P2 1 | 0 | 0 |
| Beijing Biostar Pharmaceuticals Co., Ltd. | 1 | P2 1 | 0 | 1 |
| Beijing Biotech new entrant | 1 | P2 1 | 1 | 1 |
New-entrant sponsors: Actithera INC., Beijing Biotech.
Recently stopped trials
- NCT05065957 InnoPharmax Inc. - terminated: Dose-finding stage has been completed, and dose-expanding stage was not conducted due to design amendment. Study of Combination Therapy of D07001-Softgel Capsules and Xeloda/TS-1 in Subjects With Advanced Biliary Tract Cancer
Upcoming trial readouts (next 90 days)
| Readout | Phase | Sponsor | Trial | Conditions | Status | Enrollment |
|---|---|---|---|---|---|---|
| 2026-12 est. | P2 | Taiho Oncology, Inc. | NCT05727176 Study of Futibatinib in Patients With Advanced Cholangiocarcinoma With FGFR2 Fusion or Rearrangement | Advanced Cholangiocarcinoma; FGFR2 Fusions; Gene Rearrangement | recruiting | 120 |
| 2026-12 est. | P1/P2 | TiumBio Co., Ltd. | NCT05784688 Study of TU2218 in Combination With KEYTRUDA®(Pembrolizumab) in Patients With Advanced Solid Tumors | Solid Tumor; Biliary Tract Cancer; Head and Neck Squamous Cell Carcinoma; Colorectal Cancer | recruiting | 140 |
| 2026-12 est. | P3 | TransThera Sciences (Nanjing), Inc. | NCT05948475 Study of Tinengotinib VS. Physician's Choice a Treatment of Subjects With FGFR-altered in Cholangiocarcinoma | Cholangiocarcinoma | active not recruiting | 200 |
| 2026-12 est. | P3 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | NCT05987358 A Clinical Study of TQB3454 Tablets in the Treatment of Advanced Biliary Carcinoma. | Biliary Carcinoma | active not recruiting | 165 |
| 2026-12-17 est. | P3 | Ipsen | NCT06730061 A Study of Elafibranor in Adult Japanese Participants With Primary Biliary Cholangitis (PBC) | Primary Biliary Cholangitis | active not recruiting | 18 |
| 2026-12-30 est. | P2 | Suzhou Suncadia Biopharmaceuticals Co., Ltd. | NCT06465563 SHR-8068 in Combination With Adebrelimab, Bevacizumab, and Platinum-Based Chemotherapy as First-line Treatment in Patients With Advanced Biliary Tract Cancer | Biliary Tract Cancer | active not recruiting | 93 |
| 2026-12-30 est. | P1/P2 | Astellas Pharma Global Development, Inc. | NCT06792435 XNW27011 Study of Advanced Solid Tumor Subjects Who Failed Standard Therapies. | Pancreatic Adenocarcinoma Metastatic; Lung Cancer (NSCLC); Ovarian Cancer; Colorectal Cancer Metasta | active not recruiting | 240 |
| 2026-12-31 est. | P2 | Jiangsu HengRui Medicine Co., Ltd. | NCT06413745 Phase II Clinical Study of SHR-A1811 in Patients With HER2 Expression / Amplification of Locally Advanced Unresectable or Recurrent Metastatic Biliary Tract Can | HER2 Expression / Amplification in Patients With Biliary Tract Cancer | active not recruiting | 59 |
| 2026-12-31 est. | P2 | Shanghai Pharmaceuticals Holding Co., Ltd | NCT06434597 A Clinical Study of SPH5030 Tablets in the Treatment of Her2-positive/Mutated Biliary Tract OR Colorectal Cancer Patients. | Biliary Tract or Colorectal Cancer With Her2-positive/Mutated | recruiting | 60 |
| 2026-12-31 est. | P2 | Valenta Pharm JSC | NCT06842966 Efficacy, Safety, and Tolerability of 4-MUST Tablets in Chronic Cholecystitis and Biliary Dyskinesia | Chronic Cholecystitis; Biliary Dyskinesia | recruiting | 300 |
| 2027-01 est. | P2 | Mirum Pharmaceuticals, Inc. MIRM | NCT05050136 A Study to Evaluate Efficacy and Safety of an Investigational Drug Named Volixibat in Patients With Itching Caused by Primary Biliary Cholangitis | Primary Biliary Cholangitis; PBC | active not recruiting | 333 |
Readouts in the last 180 days
| Readout | Phase | Sponsor | Trial | Conditions | Status | Enrollment |
|---|---|---|---|---|---|---|
| 2026-11-17 est. | P2 | AstraZeneca AZN | NCT06219941 AZD0901 in Participants With Advanced Solid Tumours Expressing Claudin18.2 | Gastric Cancer; Gastroesophageal Junction Cancer; Biliary Tract Cancer; Pancreatic Ductal Adenocarci | recruiting | 226 |
| 2026-10-29 | P2 | Hoffmann-La Roche | NCT02568267 Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1/2/3 (Trk A/B/C), ROS1, or ALK Gene Rearrangements (Fusio | Breast Cancer; Cholangiocarcinoma; Colorectal Cancer; Head and Neck Neoplasms; Lymphoma, Large-Cell, | completed | 534 |
| 2026-10-28 est. | P3 | Albireo, an Ipsen Company | NCT05426733 An Open-label Extension Study to Evaluate Long-term Efficacy and Safety of Odevixibat in Children With Biliary Atresia | Biliary Atresia | active not recruiting | 180 |
| 2026-10-27 est. | P2 | AstraZeneca AZN | NCT05775159 Study of Novel Immunomodulators as Monotherapy and in Combination With Anticancer Agents in Participants With Advanced Hepatobiliary Cancer | Hepatocellular Carcinoma; Biliary Tract Cancer | active not recruiting | 294 |
| 2026-10 est. | P2 | Qilu Pharmaceutical Co., Ltd. | NCT07151872 Combination of QLS31905 and Chemotherapy ± QL2107 in Patients With CLDN18.2-positive Advanced Biliary Tract Cancer | CLDN18.2-positive Advanced Biliary Tract Cancer | not yet recruiting | 120 |
| 2026-10 est. | P3 | Akeso | NCT06591520 AK112 Combined With Chemotherapy Versus Durvalumab Combined With Chemotherapy in Advanced Biliary Tract Cancer | Biliary Tract Cancer | active not recruiting | 682 |
| 2026-09-09 | P1/P2 | Umecrine Cognition AB | NCT07304843 A Two-part Study to Investigate the Effects in Adults of Two Doses of Golexanolone in Patients With Primary Biliary Cholangitis (PBC) With Fatigue and Cognitive | Primary Biliary Cholangitis (PBC) | completed | 207 |
| 2026-06-22 | P3 | Albireo, an Ipsen Company | NCT04336722 Efficacy and Safety of Odevixibat in Children With Biliary Atresia Who Have Undergone a Kasai HPE (BOLD) | Biliary Atresia | completed | 254 |
| 2026-06-16 | P3 | Ipsen | NCT06383403 A Study of Elafibranor in Adults With Primary Biliary Cholangitis and Inadequate Response or Intolerance to Ursodeoxycholic Acid. | Primary Biliary Cholangitis | completed | 92 |
Landscape counts: ClinicalTrials.gov, industry lead sponsors, active statuses, via the free hosted BioCatalystFeed MCP tool condition_landscape (query "biliary tract cancer"); readouts matched by condition text. Registry counts only; not a forecast.
Readout = ClinicalTrials.gov primary completion date (sponsor-reported; est. dates often slip; top-line
results usually follow weeks to months later). FDA events: PDUFA dates are extracted from company 8-K filings (SEC EDGAR) and are
company-disclosed and UNVERIFIED - read the filing; AdCom meetings come from Federal Register notices; approvals from Drugs@FDA
(openFDA); complete response letters from openFDA (published with a lag). Tickers are matched by name with a confidence score.
Generated 2026-11-18T17:57:33Z. Same data: bcf readouts search, bcf fda-decisions search, MCP
readout_calendar / fda_decisions. Not investment advice.